Disc Medicine, Inc.
IRON Healthcare Biotechnology
- EPS
- +2.53%
- Free cash flow
- +7.83%
- Total debt
- +106.5%
Quarter to June 2026, against a year earlier
Follow IRON
Alert me
Disc Medicine, Inc. (IRON) Book value per share
Disc Medicine, Inc.'s book value per share at the end of fiscal 2025 was 21.0×, up 30.4% from 16.1× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 16.7×. Over the past ten years it has ranged from −73.1× (fiscal 2021) to 170× (fiscal 2022); the current reading is higher than 67% of that period. Disc Medicine, Inc. ranks 44th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 21.0× | 30.45% |
| FY2024 | 16.1× | 3.90% |
| FY2023 | 15.5× | (90.90%) |
| FY2022 | 170× | 0.05% |
| FY2022 | 170× | — |
| FY2021 | −73.1× | — |
| FY2021 | 88.4× | — |
| FY2020 | −14.5× | — |
| FY2020 | −14.5× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 16.7× | (6.90%) |
| Mar 2026 | 17.9× | (14.67%) |
| Dec 2025 | 21.0× | 28.60% |
| Sep 2025 | 16.3× | (7.05%) |
| 22 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| PBLS Parabilis Medicines, Inc. compare | 36.2× |
| IRON Disc Medicine, Inc. | 16.7× |
| XENE Xenon Pharmaceuticals Inc. compare | 12.5× |
| ACAD ACADIA Pharmaceuticals Inc. compare | 8.0× |
| TNGX Tango Therapeutics, Inc. compare | 6.8× |
| VKTX Viking Therapeutics, Inc. compare | 5.0× |
| RLAY Relay Therapeutics, Inc. compare | 4.4× |
| DYN Dyne Therapeutics, Inc. compare | 4.2× |
| IOVA Iovance Biotherapeutics, Inc. compare | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))